

Bereskin & Parr



RECEIVED

NOV 25 2002

November 20, 2002 **TECH CENTER 1600/2900**

Barristers and Solicitors/Patent and Trade Mark Agents
Practice Restricted to Intellectual Property Law

Micheline Gravelle B.Sc., M.Sc. (Immunol.)
416 957 1682 mgravelle@bereskinparr.com

Your Reference: 09/917,278
Our Reference: 9579-39

13
JM
11/25/02

RECEIVED
TECH CENTER 1600/2900
02 NOV 21 PM 12:27

Commissioner for Patents and Trademarks
Washington, D.C. 20231
U.S.A.

Dear Sir:

Re: SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
United States Patent Application No. 09/917,278
Entitled: Methods and Compositions For Tumor Growth
Inventors: Reginald M. Gorczynski and David Clark
Filing Date: July 30, 2001
Examiner: Jessica H. Roark
Art Unit: 1644

In accordance with 37 CFR 1.97 and 1.98, and in recognition of the duty of disclosure set forth in 37 CFR 1.56, Applicant hereby submits a Supplemental Information Disclosure Statement on Form PTO-1449 containing a listing of patents and other publications of which Applicant is aware. Applicant is also submitting the references listed on the Information Disclosure Statement.

All of the patents and publications submitted herewith are in the English language. Accordingly a concise explanation of the relevance of the documents is not required.

11/22/2002 TSUGGS 00000001 09917278

01 FC:1806

180.00 DP

please send your reply to:

Scotia Plaza, 40 King Street West, 40th Floor
Toronto, Ontario, Canada M5H 3Y2
416 364 7311 fax: 416 361 1398

Meadowvale Corporate Centre, 2000 Argentia Road
Plaza 4, Suite 430, Mississauga, Ontario, Canada L5N 1W1
905 812 3600 fax: 905 814 0031

www.bereskinparr.com

The Examiner is requested to indicate consideration of these documents by initialling the appropriate column.


This Information Disclosure Statement is being filed after the mailing date of a first Office Action; therefore, the government fee of \$180.00 as provided in 37 CFR 1.17(p) is included in our cheque No. 4763 .

Applicants reserve the right to contest the applicability of any of these documents as prior art against the subject application. If the Examiner has any questions concerning this Information Disclosure Statement, he is requested to contact the undersigned. Entry of the enclosed Information Disclosure Statement is believed to be in order and is respectfully requested.

If additional fees are required, please charge the fees to our Deposit Account No. 02-2095.

Respectfully submitted,

Reginald M. Gorczynski and David Clark

A handwritten signature in cursive script, appearing to read "M. Gravelle", written over a horizontal line.

Micheline Gravelle
Registration No. 40,261

Bereskin & Parr
Box 401, 40 King Street West
Toronto, Ontario, Canada
M5H 3Y2

Tel. (416) 364-7311